NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

QNRX

Quoin Pharmaceuticals Ltd ADR

Apr 04 • 01:32PM ET

0.2403

Dollar change -0.0198
Percentage change -7.61	%

Healthcare • Biotechnology • USA • NASD

Peers: ASND RDHL MDGL XENE TGTX CRIS VYGR ADAP MREO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.34	Insider Own	-	Shs Outstand	8.95M	Perf Week	-0.62%
Market Cap	2.15M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	-	Shs Float	5.03M	Perf Month	-19.95%
Income	-9.01M	PEG	-	EPS next Q	-0.20	Inst Own	17.28%	Short Float	17.27%	Perf Quarter	-64.21%
Sales	0.00M	P/S	-	EPS this Y	33.51%	Inst Trans	1.79%	Short Ratio	0.10	Perf Half Y	-50.02%
Book/sh	1.03	P/B	0.23	EPS next Y	68.50%	ROA	-64.61%	Short Interest	0.87M	Perf Year	-73.00%
Cash/sh	1.57	P/C	0.15	EPS next 5Y	-	ROE	-121.15%	52W Range	0.21 - 1.57	Perf YTD	-63.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-143.98%	ROI	-97.85%	52W High	-84.69%	Beta	1.27
Dividend TTM	-	Quick Ratio	3.57	Sales past 5Y	0.00%	Gross Margin	-	52W Low	14.32%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	3.57	EPS Y/Y TTM	42.26%	Oper. Margin	-	RSI (14)	40.84	Volatility	30.35% 12.28%
Employees	5	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.48
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	83.19%	Payout	-	Rel Volume	0.26	Prev Close	0.26
Sales Surprise	-	EPS Surprise	23.91%	Sales Q/Q	-	Earnings	Mar 13 BMO	Avg Volume	8.87M	Price	0.24
SMA20	-14.25%	SMA50	-20.44%	SMA200	-55.82%	Trades		Volume	1,479,233	Change	-7.61%

Apr-02-25 07:30AM	Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient (GlobeNewswire) +38.23%
Mar-25-25 07:30AM	Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases (GlobeNewswire) -5.00%
Mar-13-25 07:30AM	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Mar-06-25 08:00AM	Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025 (GlobeNewswire) -7.35%
Mar-04-25 07:30AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications (GlobeNewswire)
07:30AM	Loading…
Feb-27-25 07:30AM	Quoin Pharmaceuticals Announces Highly Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study (GlobeNewswire) +15.40%
Feb-25-25 07:30AM	Quoin Pharmaceuticals Launches First Episode of "NETHERTON NOW" Video Series to Raise Awareness for Netherton Syndrome (GlobeNewswire)
Feb-04-25 07:30AM	Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure (GlobeNewswire)
Jan-23-25 08:30AM	Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome (GlobeNewswire) -30.22%
05:30AM	Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies (ACCESSWIRE)
Jan-14-25 08:30AM	Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study (GlobeNewswire)
Jan-07-25 02:29PM	PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials (GlobeNewswire)
Jan-06-25 08:30AM	Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study (GlobeNewswire)
Dec-20-24 09:20AM	Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering (GlobeNewswire) -12.03%
Dec-19-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study (GlobeNewswire) +14.99%
08:18AM	Loading…
Dec-18-24 08:18AM	Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire) -6.65%
Nov-07-24 08:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 08:00AM	Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient (GlobeNewswire)
Oct-31-24 04:05PM	Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024 (GlobeNewswire) -7.78%
Oct-22-24 08:00AM	Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome (GlobeNewswire) -13.03%
Sep-09-24 08:30AM	Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO (GlobeNewswire) +24.71%
Aug-08-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results (GlobeNewswire) -7.17%
Aug-06-24 05:00AM	Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome (GlobeNewswire)
Aug-01-24 04:10PM	Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jun-27-24 08:00AM	Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome (GlobeNewswire)
Jun-25-24 04:05PM	Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference (GlobeNewswire)
Jun-12-24 08:00AM	Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland (GlobeNewswire)
May-09-24 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 04:10PM	Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire) +6.34%
Mar-15-24 10:52AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
04:05PM	Loading…
Mar-13-24 04:05PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results (GlobeNewswire) -13.79%
Mar-07-24 04:05PM	Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET (GlobeNewswire) -8.47%
Mar-05-24 08:34AM	Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today? (InvestorPlace) -48.28%
08:00AM	Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering (GlobeNewswire)
Mar-04-24 08:00AM	Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies (GlobeNewswire)
Feb-14-24 09:00AM	Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome (ACCESSWIRE)
Feb-08-24 08:00AM	Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product (GlobeNewswire)
Dec-13-23 08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome (GlobeNewswire)
Nov-10-23 12:19PM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:46PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results (GlobeNewswire) -8.26%
Nov-03-23 08:41AM	Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET (GlobeNewswire)
Oct-24-23 09:32AM	REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire) +8.04%
08:28AM	Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome (GlobeNewswire)
Oct-02-23 12:25PM	QNRX: Positive Early Clinical Data, Moving QRX003 Through Multiple Trials (Zacks)
Aug-09-23 08:30AM	Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders (NewMediaWire)
Aug-02-23 04:45PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results (GlobeNewswire) -10.67% +6.26%
Jul-27-23 08:00AM	Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET (GlobeNewswire)
May-24-23 08:15AM	Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial (GlobeNewswire)
May-08-23 05:00PM	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results (GlobeNewswire) +14.90% -14.23%
May-02-23 08:30AM	Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET (GlobeNewswire)
Mar-22-23 09:13AM	QNRX: Patients Dosed in Both Concurrent Studies; Potentially Adding New Assets to Product Portfolio (Zacks Small Cap Research) +5.92%
Mar-21-23 08:30AM	Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial (GlobeNewswire)
Mar-11-23 02:59AM	Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 05:08PM	Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -7.83%
Mar-02-23 04:05PM	Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET (GlobeNewswire)
Mar-01-23 08:30AM	A Pivotal Year Ahead for Quoin Pharmaceuticals (NewMediaWire)
Feb-22-23 08:39AM	Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -47.90%
Dec-13-22 08:30AM	Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome (GlobeNewswire)
Dec-05-22 11:15AM	QNRX: Moving QRX003 Forward in Concurrent Studies (Zacks Small Cap Research)
Nov-10-22 08:30AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results (GlobeNewswire) +17.07%
Nov-03-22 07:00AM	Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th (GlobeNewswire)
Nov-01-22 08:30AM	Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th (GlobeNewswire)
Oct-18-22 08:30AM	Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients (GlobeNewswire) +44.44%
Sep-13-22 08:30AM	Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study (GlobeNewswire) -7.75%
Aug-23-22 01:43PM	QNRX: Enhanced Financial Flexibility to Move QRX003 & Other Assets Forward (Zacks Small Cap Research) -9.13%
Aug-18-22 07:00AM	Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results (GlobeNewswire) -10.40%
Aug-11-22 04:30PM	Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th (GlobeNewswire)
Aug-09-22 04:23PM	Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering (GlobeNewswire) -8.77%
Aug-05-22 09:28AM	Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering (GlobeNewswire) -62.38%
Jul-28-22 08:30AM	Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe (GlobeNewswire)
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada (Zacks)
Jul-15-22 08:30AM	Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements (GlobeNewswire) -12.75%
07:30AM	Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada (PR Newswire)
Jul-06-22 08:30AM	Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study (GlobeNewswire) +13.18%
Jun-15-22 04:01PM	Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) -14.60% -10.11%
08:30AM	Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China (GlobeNewswire)
Jun-14-22 08:30AM	Quoin Pharmaceuticals: Strategically Building For Future Success (Newsfile) +6.02%
Jun-10-22 10:23AM	15 Best Penny Stocks To Invest In (Insider Monkey)
Jun-06-22 11:22AM	Why Are Quoin Pharma Shares Trading Higher Today? (Benzinga) -7.50%
08:00AM	Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug (ACCESSWIRE)
May-23-22 08:30AM	Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University (GlobeNewswire)
May-17-22 08:30AM	Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome (Newsfile) +12.64%
May-11-22 11:24AM	When Will Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Breakeven? (Simply Wall St.) -8.48%
Apr-25-22 01:05PM	QNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications (Zacks Small Cap Research) +10.00%
08:30AM	Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Mar-24-22 08:30AM	Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024 (Newsfile)
Mar-15-22 08:41AM	Quoin Pharmaceuticals Announces Submission of IND for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Mar-10-22 08:00AM	Quoin Pharmaceuticals Submits Scientific Advice Briefing Document to EMA for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) +14.34%
Mar-01-22 08:00AM	Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) +5.41%
Feb-17-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Neopharm for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Feb-10-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with ER-Kim for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire)
Feb-08-22 08:30AM	Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy (Newsfile)
Jan-26-22 08:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with OrphanDC for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) -6.52%
Jan-24-22 07:15AM	QNRX: Laying the Groundwork to Launch Multiple Treatments for Rare & Orphan Diseases (Zacks Small Cap Research)
Dec-15-21 09:00AM	Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Orpharm LLC for its Lead Asset, QRX003, for Netherton Syndrome (GlobeNewswire) -12.58%
Dec-14-21 08:30AM	The R&D Sweet Spot: Quoin Pharmaceuticals Delivering Value-Based Drug Development Through Rare and Orphan Disease Therapeutics (Newsfile)
Nov-16-21 08:30AM	Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising Pipeline (Newsfile)
Nov-11-21 08:30AM	Quoin Pharmaceuticals and Genpharm Services Sign Exclusive License and Distribution Agreement for Quoins Lead Asset, QRX003 (GlobeNewswire) -21.74%
Nov-08-21 08:00AM	Quoin Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with AFT Pharmaceuticals for its Lead Asset, QRX003 (GlobeNewswire) -8.94%
Nov-04-21 09:25AM	Quoin Pharmaceuticals Appoints Gordon Dunn as Chief Financial Officer (GlobeNewswire)

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carter Denise P.	Chief Operating Officer	Dec 23 '24	Buy	0.45	555,556	250,000	602,648	Dec 27 05:17 PM
Myers Michael	Chief Executive Officer	Dec 23 '24	Buy	0.45	555,556	250,000	602,808	Dec 27 05:16 PM
Dunn Gordon	Chief Financial Officer	Dec 23 '24	Buy	0.45	122,221	54,999	151,077	Dec 27 05:16 PM
Culverwell Anthony James	Director	Dec 23 '24	Buy	0.45	100,000	45,000	100,317	Dec 27 05:15 PM
Dunn Gordon	Chief Financial Officer	Sep 10 '24	Buy	0.81	20,000	16,200	28,856	Sep 11 04:30 PM
Dunn Gordon	Chief Financial Officer	Sep 09 '24	Buy	0.79	8,856	7,005	8,856	Sep 11 04:30 PM
Carter Denise P.	Chief Operating Officer	Sep 04 '24	Buy	0.78	31,813	24,912	47,092	Sep 05 12:06 PM
Carter Denise P.	Chief Operating Officer	Sep 03 '24	Buy	0.65	5,922	3,825	15,279	Sep 05 12:06 PM
Myers Michael	Chief Executive Officer	Sep 04 '24	Buy	0.77	37,094	28,421	47,252	Sep 05 12:03 PM
Myers Michael	Chief Executive Officer	Sep 03 '24	Buy	0.62	800	495	10,158	Sep 05 12:03 PM
LANGER DENNIS	Director	Jun 07 '24	Sale	0.73	297	217	53	Jun 10 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QNRX

Quoin Pharmaceuticals Ltd ADR

Upgrade your FINVIZ experience